Immunohistochemical expression of cyclin, D1, E2F-1, and Ki-67 in benign and malignant thyroid lesions

Journal of Pathology

Volumn 198, Issue 2, 2002, Pages 157-162

  Saiz, Antonio D ^a   Olvera, Maria ^a   Rezk, Sherif ^a   Florentine, Barbara A ^a   McCourty, Althea ^a   Brynes, Russell K ^a,b  

^a LAC USC MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cell cycle proteins; Cyclin D1; E2F 1; Ki 67; Thyroid neoplasms

Indexed keywords

CYCLIN D1; KI 67 ANTIGEN; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F;

ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CHROMOSOME 11Q; CHROMOSOME NUMBER; CONTROLLED STUDY; DNA SYNTHESIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE ACTIVATION; GENE AMPLIFICATION; GENE LOCUS; GENE OVEREXPRESSION; GENE PROBE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; ADENOMA; CARCINOMA, PAPILLARY; CELL CYCLE PROTEINS; CELL DIVISION; CYCLIN D1; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; E2F1 TRANSCRIPTION FACTOR; HUMANS; HYPERPLASIA; IN SITU HYBRIDIZATION, FLUORESCENCE; KI-67 ANTIGEN; NEOPLASM PROTEINS; THYROID GLAND; THYROID NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 0036773453     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1185     Document Type: Article

References (24)

1. Helin K. Regulation of cell proliferation by the E2F transcription factors. Curr Opin Genet Dev 1998; 8: 28-35.
2. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 1998; 12: 2245-2262.
3. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-330.
4. Sellers WR, Kaelin WG. Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol 1997; 15: 3301-3312.
5. Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet 2001; 10: 699-703.
6. Zheng N, Fraenkel E, Pabo CO, Pavletich NP. Structural basis of DNA recognition by the heterodimeric cell cycle transcription factor E2F-DP. Genes Dev 1999; 13: 666-674.
7. Zhu XL, Hartwick W, Rohan T, Kandel R. Cyclin D1 gene amplification and protein expression in benign breast disease and breast carcinoma. Mod Pathol 1998; 11: 1082-1088.
8. Rennstam K, Baldetorp B, Kytola S, Tanner M, Isola J. Chromosomal rearrangements and oncogene amplification precede aneuploidization in the genetic evolution of breast cancer. Cancer Res 2001; 61: 1214-1219.
9. Smith BD, Haffty BG, Sasaki CT, et al. Molecular markers in head and neck squamous cell carcinoma: their biological function and prognostic significance. Ann Otol Rhinol Laryngol 2001; 110: 221-228.
10. Takagi Y, Takashi M, Koshikawa T, Sakata T, Ohshima S. Immunohistochemical demonstration of cyclin D1 in bladder cancers as an inverse indicator of invasiveness but not an independent prognostic factor. Int J Urol 2000; 7: 366-372.
11. Tut VM, Braithwaite KL, Angus B, Neal DE, Lunec J, Mellon JK. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67. Br J Cancer 2001; 84: 270-275.
12. Williams ME, Westermann CD, Swerdlow SH. Genotypic characterization of centrocytic lymphoma: frequent rearrangement of the chromosome 11 bcl-1 locus. Blood 1990; 76: 1387-1391.
13. Katz RL, Caraway NP, Gu J, et al. Detection of chromosome 11q13 breakpoints by interphase fluorescence in situ hybridization of mantle cell lymphoma. Am J Clin Pathol 2000; 114: 248-257.
14. Muro-Cacho CA, Munoz-Antonia T, Livingston S, Klotch D. Transforming growth factor beta-receptors and p27kip in thyroid carcinoma. Arch Otolaryngol Head Neck Surg 1999; 125: 76-81.
15. Erickson LA, Jin L, Goellner JR, et al. Pathologic features, proliferative activity, and cyclin D1 expression in Hürthle cell neoplasms of the thyroid. Mod Pathol 2000; 13: 186-192.
16. Wang S, Wuu J, Savas L, Patwardhan N, Khan A. The role of cell cycle regulatory proteins, cyclin D1 cyclin E, and p27 in thyroid carcinogenesis. Hum Pathol 1998; 29: 1304-1309.
17. Muro-Cacho CA, Holt T, Klotch D, et al. Cyclin D1 expression as a prognostic parameter in papillary carcinoma of the thyroid. Otolaryngol Head Neck Surg 1999; 120: 200-207.
18. Zou M, Shi Y, Farid NR, Al-Sedairy ST. Inverse association between cyclin D1 overexpression and retinoblastoma gene mutation in thyroid carcinomas. Endocrine 1998; 8: 61-64.
19. Wang S, Lloyd RV, Hutzler MJ, et al. The role of cell cycle regulatory protein, cyclin D1, in the progression of thyroid cancer. Mod Pathol 2000; 13: 882-887.
20. Basolo F, Caligo MA, Pinchera A, et al. Cyclin D1 overexpression in thyroid carcinomas: relation with clinicopathologic parameters, retinoblastoma gene product, and Ki67 labeling index. Thyroid 2000; 10: 741-746.
21. Lazzereschi D, Sambuco L, Carnovale SC, et al. Cyclin D1 and cyclin E expression in malignant thyroid cells and in human thyroid carcinomas. Int J Cancer 1998; 76: 806-811.
22. Lai R, Medeiros LJ, Coupland R, McCourty A, Brynes RK. Immunohistochemical detection of E2F-1 in non-Hodgkin's lymphomas: a survey of 124 cases. Mod Pathol 1998; 11: 457-463.
23. Lai R, Medeiros LJ, Wilson CS, et al. Expression of the cell-cycle-related proteins E2F-1 p53, mdm-2, p21waf-1, and Ki-67 in multiple myeloma: correlation with cyclin-D1 immunoreactivity. Mod Pathol 1998; 11: 642-647.
24. Wilson CS, Butch AW, Lai RM, et al. Cyclin D1 and E2F-1 immunoreactivity in bone marrow biopsy specimens of multiple myeloma: relationship to proliferative activity, cytogenetic abnormalities and DNA ploidy. Br J Haematol 2001; 112: 776-782.